Filing Flows › Corcept Therapeutics (CORT) › Next earnings date
Corcept Therapeutics (CORT) earnings: beat the estimate
Corcept Therapeutics (CORT) reported on Nov 3, 2026 and beat the EPS estimate: $1.01 against $0.84 (+20.2%). Revenue was $340M for Q3 2026, +64% year over year. It beat the EPS estimate in 60% of the quarters on record.
The last report
Corcept Therapeutics reported revenue of $340M for the third quarter 2026 (+64% Y/Y), net earnings $127M: Hypercortisolism Products $249M, Lifyorli $91.4M. How it makes money → · Every quarter →
Corcept Therapeutics' latest quarter
Corcept Therapeutics, Q3 2026: revenue $340M (+64% year over year), operating margin 33.7%, net earnings $127M, operating cash flow $143M. The chart follows the revenue to costs, profit and cash.
Questions
Did Corcept Therapeutics beat earnings?
Corcept Therapeutics (CORT) reported on Nov 3, 2026 and beat the EPS estimate: $1.01 against $0.84 (+20.2%).
When does CORT report earnings?
The next date is not set yet.
Does Corcept Therapeutics usually beat earnings?
It beat the consensus EPS estimate in 60% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.